Hormone Therapy

A recent study found that men were more likely than women to have cardiovascular complications during hospitalization with COVID-19.

Menopausal hormone therapy for bothersome vasomotor or other symptoms is safe and appropriate for most women at low atherosclerotic CVD risk, whereas a nuanced approach is needed for intermediate-risk women, researchers reported.

Transgender and nonbinary youths had greater appearance congruence — the experience that physical appearance aligns with gender —and less depression and anxiety after 2 years of gender-affirming hormone therapy, according to study data.

Postmenopausal women with hypertension taking estrogen alone or combined with progesterone had a statistically significant increase in systolic blood pressure compare with placebo, according to an analysis of WHI data.

Among postmenopausal women with vulvovaginal atrophy, ospemifene treatment and hormone therapy improved the vaginal microbiome in different ways, according to findings published in Menopause.

Hormone therapy may promote better memory and cognitive function and larger brain volumes among women carrying APOE4, a genetic risk factor for Alzheimer’s disease.

Two studies published in Menopause demonstrated hormone therapy and selective serotonin reuptake inhibitors/serotonin norepinephrine reuptake inhibitors as generally effective therapies for menopausal symptoms.

Over the past year, the U.S. Preventive Services Task Force has released recommendations on screening and preventive treatment for various medical conditions

Healio and Cardiology Today have compiled a list of the most-read news of 2022 in CHD and prevention.

A pilot study published in Menopause highlighted racial disparities in the acceptance of systemic and local hormone therapy in perimenopausal and postmenopausal women.